Gocovri for Parkinson's Disease User Reviews
- Suz...
- Taken for 1 to 6 months
- December 7, 2023
"Gocovri has reduced the length of time of my dyskinesia and reduced the severity as well. I am forced to go off of it due to the cost. Seems like the cost could be reduced to have more users. I can't afford $900 per month and then the donut hole! Back to Amantadine IR."
Are you taking this medicine?
Your review helps others make informed decisions.Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
Learn more about Parkinson's Disease
Care guides
Symptoms and treatments
Medicine.com guides (external)
More about Gocovri (amantadine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: dopaminergic antiparkinsonism agents
- Breastfeeding
- En español
"Gocovri seemed to be better at controlling dyskinesia than Amantadine. There was less abdominal cramping in the morning. I was taking the 68.5 mg capsule, which is the lowest dose before bedtime. However, Gocovri is very expensive. My co-pay was close to $450 per month. I felt the difference in comparing the two medications' ability to control the dyskinesia was not sufficient enough to warrant the excessive cost of Gocovri."